ATLAS News · Deals

Johnson & Johnson to Acquire Ollin Biosciences in Deal Worth Up to $3.33 Billion

· 1 sources

MarketScreener reports Johnson & Johnson will acquire Ollin Biosciences in a transaction valued at up to $3.33 billion.

What happened

Johnson & Johnson (JNJ) is set to acquire Ollin Biosciences, according to MarketScreener. The outlet reports that the transaction is valued at up to $3.33 billion.

The wording of the report, "up to", indicates that the total figure may include amounts beyond an initial payment. The source provided to ATLAS does not detail the deal structure, timing or conditions.

Context

Large pharmaceutical and healthcare companies often acquire smaller biotechnology firms to add to their research and product pipelines.

Why it matters

The deal may be of interest to investors following Johnson & Johnson because it points to how the company is allocating capital toward acquisitions.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

Healthcare · NYSE

Live price
$289.02▲ +1.14%

live price · USD

Latest price during the session
$289.02+1.14% vs. previous close ($285.76)
Fair value (ATLAS)
$200.74Fair range: $127.36 to $271.34The price ($289.02) is 44.0% above that figure.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $278.05 and $302.44; 9 in 10, between $258.07 and $325.85.
See the full ATLAS analysis of Johnson & Johnson →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

  1. Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.33 Billion · marketscreener.com · November 16, 2026

Related

Latest market news · Markets today on ATLAS · Johnson & Johnson

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer

ATLAS Signals

ATLAS Signals, every week

The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.

By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy